Sophia N Karagiannis
Sophia N Karagiannis
Professor of Translational Cancer Immunology and Immunotherapy, King’s College London
Verified email at - Homepage
Cited by
Cited by
Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation
CC Chu, N Ali, P Karagiannis, P Di Meglio, A Skowera, L Napolitano, ...
Journal of Experimental Medicine 209 (5), 935-945, 2012
Targeting folate receptor alpha for cancer treatment
A Cheung, HJ Bax, DH Josephs, KM Ilieva, G Pellizzari, J Opzoomer, ...
Oncotarget 7 (32), 52553, 2016
AllergoOncology: the role of IgE‐mediated allergy in cancer
E Jensen‐Jarolim, G Achatz, MC Turner, S Karagiannis, F Legrand, ...
Allergy 63 (10), 1255-1266, 2008
IgG4 subclass antibodies impair antitumor immunity in melanoma
P Karagiannis, AE Gilbert, DH Josephs, N Ali, T Dodev, L Saul, I Correa, ...
The Journal of Clinical Investigation 123 (4), 1457-1474, 2013
Comparison of IgE and IgG antibody‐dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma
HJ Gould, GA Mackay, SN Karagiannis, CM O'Toole, PJ Marsh, BE Daniel, ...
European journal of immunology 29 (11), 3527-3537, 1999
Diverse matrix metalloproteinase functions regulate cancer amoeboid migration
JL Orgaz, P Pandya, R Dalmeida, P Karagiannis, B Sanchez-Laorden, ...
Nature communications 5 (1), 1-13, 2014
IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells
SN Karagiannis, MG Bracher, J Hunt, N McCloskey, RL Beavil, AJ Beavil, ...
The Journal of Immunology 179 (5), 2832-2843, 2007
Activity of human monocytes in IgE antibody‐dependent surveillance and killing of ovarian tumor cells
SN Karagiannis, Q Wang, N East, F Burke, S Riffard, MG Bracher, ...
European journal of immunology 33 (4), 1030-1040, 2003
Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells
P Karagiannis, J Singer, J Hunt, SKE Gan, SM Rudman, ...
Cancer immunology, immunotherapy 58 (6), 915-930, 2009
Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma
DO Khair, HJ Bax, S Mele, S Crescioli, G Pellizzari, A Khiabany, ...
Frontiers in immunology 10, 453, 2019
TGF-β-induced transcription sustains amoeboid melanoma migration and dissemination
G Cantelli, JL Orgaz, I Rodriguez-Hernandez, P Karagiannis, O Maiques, ...
Current biology 25 (22), 2899-2914, 2015
A tool kit for rapid cloning and expression of recombinant antibodies
TS Dodev, P Karagiannis, AE Gilbert, DH Josephs, H Bowen, LK James, ...
Scientific reports 4 (1), 1-10, 2014
Epidemiological associations of allergy, IgE and cancer
DH Josephs, JF Spicer, CJ Corrigan, HJ Gould, SN Karagiannis
Clinical & Experimental Allergy 43 (10), 1110-1123, 2013
Endocytosis and recycling of the complex between CD23 and HLA‐DR in human B cells
SN Karagiannis, JK Warrack, KH Jennings, PR Murdock, G Christie, ...
Immunology 103 (3), 319-331, 2001
Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells
SN Karagiannis, MG Bracher, RL Beavil, AJ Beavil, J Hunt, N McCloskey, ...
Cancer Immunology, Immunotherapy 57 (2), 247-263, 2008
An atlas of human regulatory T helper-like cells reveals features of Th2-like Tregs that support a tumorigenic environment
L Halim, M Romano, R McGregor, I Correa, P Pavlidis, N Grageda, ...
Cell reports 20 (3), 757-770, 2017
Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma
KM Ilieva, I Correa, DH Josephs, P Karagiannis, IU Egbuniwe, ...
Molecular cancer therapeutics 13 (12), 2769-2783, 2014
Evaluating biomarkers in melanoma
P Karagiannis, M Fittall, SN Karagiannis
Frontiers in oncology 4, 383, 2015
Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis
M Bracher, HJ Gould, BJ Sutton, D Dombrowicz, SN Karagiannis
Journal of immunological methods 323 (2), 160-171, 2007
Regional activation of myosin II in cancer cells drives tumor progression via a secretory cross-talk with the immune microenvironment
M Georgouli, C Herraiz, E Crosas-Molist, B Fanshawe, O Maiques, ...
Cell 176 (4), 757-774. e23, 2019
The system can't perform the operation now. Try again later.
Articles 1–20